⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 12, 2025Open Access

Table 1 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895

Jack C. Stromatt Eman Ahmed Thomas Drabison Mahesh R. Nepal Anika T. Chowdhury Shelley Orwick Daelynn R. Buelow Eric D. Eisenmann Kevin M. Huang Alex Sparreboom Sharyn D. Baker

View Full Paper

Ask AI

Bookmark

Share

Key Points

Pharmacokinetic properties of TL-895 are affected by mouse strain and sex, ensuring dosing accuracy.
The CYP3A genotype significantly influences TL-895's pharmacokinetics across different conditions.
Dose variations markedly impact the pharmacokinetic profile of BTK inhibitor TL-895 in various mouse strains.
Study findings recommend tailoring drug dosing regimens based on CYP3A genotypes for optimized efficacy.

Implication

Analysis demonstrates pharmacokinetic variations of TL-895 influenced by strain and CYP3A genotype, suggesting personalized dosing approaches.

Abstract

Dependence of TL-895 pharmacokinetics on mouse strain, CYP3A genotype, TL-895 dose, and sex

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stromatt et al. (2025) studied this question.

synapsesocial.com/papers/68d4605131b076d99fa5fa75 https://doi.org/10.1158/2767-9764.30111347

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 2 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-8952025
2Supplementary Figure S3 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-8952025
3Supplementary Figure S4 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-8952025
4Figure 3 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-8952025
5Supplementary Figure S2 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-8952025

More related papers

Data from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-8952025
Drug-drug interaction liabilities with BTK inhibitor TL-8952025
Supplementary Figure S5 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-8952025